List view / Grid view
AI is starting to transform drug discovery, but progress is…
AI is starting to transform drug discovery, but progress is still slow and big challenges remain. Thibault Géoui explores the gaps, hurdles and breakthroughs needed before it can truly change pharma R&D.
Thibault Géoui explains why AI could finally help pharma overcome…
Thibault Géoui explains why AI could finally help pharma overcome its productivity crisis and why the payoff won’t come as quickly as the optimists claim.
An interview with Thibault Géoui reveals why this technology wave…
An interview with Thibault Géoui reveals why this technology wave might finally break through pharma's productivity crisis – and why it will take longer than the optimists claim.
As the lab–data science divide continues, Ian Kerman looks ahead…
As the lab–data science divide continues, Ian Kerman looks ahead to a future of deeper collaboration – one where shared skills, smarter tools and a shift in mindset could finally break down the barriers. In this second interview, he shares his vision, practical ideas and advice for the next generation…
In this second interview of the series, Andreas Kolleger, Head…
In this second interview of the series, Andreas Kolleger, Head of GenAI Innovation at Neo4j, discusses how knowledge graphs and AI are transforming scientific discovery and improving life sciences workflows.
In this first interview of a two-part series, Andreas Kolleger…
In this first interview of a two-part series, Andreas Kolleger explores the convergence of knowledge graphs and large language models. As the head of GenAI innovation at Neo4j, Andreas brings a unique cross-industry perspective on how these technologies can enhance life sciences workflows.
AI is transforming drug discovery, but its adoption mirrors past…
AI is transforming drug discovery, but its adoption mirrors past technological shifts in the industry. In this first part of a two-part series, we reveal Sujeegar Jeevanandam’s observations of the parallels between AI and the electronic lab notebook revolution, highlighting key challenges, lessons learned, and what the future holds for…
In this article, Dr Raminderpal Singh explores the transformative impact…
In this article, Dr Raminderpal Singh explores the transformative impact of the Deepseek R1 open-source large language model on drug discovery. Its potential offers exciting opportunities for both scientists and software developers, marking a significant advancement for the life sciences community.
In part two of the step-by-step scientific workflow for drug…
In part two of the step-by-step scientific workflow for drug discovery series, Dr Raminderpal Singh and Nina Truter describe the functions of the workflow previously outlined and include key considerations.
In this article, Dr Raminderpal Singh speaks to Janette Thomas…
In this article, Dr Raminderpal Singh speaks to Janette Thomas of Five Alarm Bio for a biotech CEO’s perspective on the complexity of data faced by both large and small biotechs. Janette is on a mission to develop drugs targeting the chronic diseases associated with ageing. She shares her insights…
In this article, Dr Raminderpal Singh speaks to Neil Wilkie…
In this article, Dr Raminderpal Singh speaks to Neil Wilkie of Mironid Ltd. for a biotech CEO’s perspective on the transformative potential of AI, and the importance of bridging communication gaps between scientific and technical teams to drive innovation and efficiency in the pharmaceutical industry.
In this four-part series, Dr Raminderpal Singh discusses the challenges…
In this four-part series, Dr Raminderpal Singh discusses the challenges surrounding limited data quality and offers some pragmatic solutions. In this fourth article, he talks to John Conway, Chief Visioneer Officer at 20/15 Visioneers for an expert perspective.
In this four-part series, Dr Raminderpal Singh will discuss the…
In this four-part series, Dr Raminderpal Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this third article, he discusses pragmatic guidelines to help support better data quality.
In this four-part series, Dr Raminderpal Singh will discuss the…
In this four-part series, Dr Raminderpal Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this second article, he discusses the problems that occur when using data of poor quality.
In this four-part series, Dr Singh will discuss the challenges…
In this four-part series, Dr Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this first article, the key attributes that define data quality and its requirement for data scientists are elucidated.
